GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Cyclically Adjusted Price-to-FCF

AngioDynamics (AngioDynamics) Cyclically Adjusted Price-to-FCF : 12.36 (As of Apr. 27, 2024)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Cyclically Adjusted Price-to-FCF?

As of today (2024-04-27), AngioDynamics's current share price is $5.81. AngioDynamics's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 was $0.47. AngioDynamics's Cyclically Adjusted Price-to-FCF for today is 12.36.

The historical rank and industry rank for AngioDynamics's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

ANGO' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 10.83   Med: 24.17   Max: 50.77
Current: 12.33

During the past years, AngioDynamics's highest Cyclically Adjusted Price-to-FCF was 50.77. The lowest was 10.83. And the median was 24.17.

ANGO's Cyclically Adjusted Price-to-FCF is ranked better than
87.34% of 229 companies
in the Medical Devices & Instruments industry
Industry Median: 42.75 vs ANGO: 12.33

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AngioDynamics's adjusted free cash flow per share data for the three months ended in Feb. 2024 was $-0.407. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.47 for the trailing ten years ended in Feb. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AngioDynamics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AngioDynamics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Cyclically Adjusted Price-to-FCF Chart

AngioDynamics Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.27 14.48 36.03 31.63 16.25

AngioDynamics Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.00 16.25 15.81 13.04 11.72

Competitive Comparison of AngioDynamics's Cyclically Adjusted Price-to-FCF

For the Medical Instruments & Supplies subindustry, AngioDynamics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Cyclically Adjusted Price-to-FCF falls into.



AngioDynamics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AngioDynamics's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=5.81/0.47
=12.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, AngioDynamics's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0.407/129.4194*129.4194
=-0.407

Current CPI (Feb. 2024) = 129.4194.

AngioDynamics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201405 0.171 100.373 0.220
201408 0.003 100.352 0.004
201411 -0.129 99.635 -0.168
201502 0.223 99.032 0.291
201505 0.265 100.333 0.342
201508 0.110 100.548 0.142
201511 0.253 100.135 0.327
201602 0.320 100.040 0.414
201605 0.408 101.355 0.521
201608 0.190 101.617 0.242
201611 0.366 101.829 0.465
201702 0.376 102.779 0.473
201705 0.496 103.256 0.622
201708 0.069 103.587 0.086
201711 0.253 104.072 0.315
201802 0.070 105.052 0.086
201805 0.619 106.148 0.755
201808 -0.256 106.383 -0.311
201811 0.326 106.338 0.397
201902 0.199 106.649 0.241
201905 0.644 108.048 0.771
201908 -0.214 108.245 -0.256
201911 0.082 108.519 0.098
202002 -0.515 109.139 -0.611
202005 0.063 108.175 0.075
202008 -0.190 109.662 -0.224
202011 0.263 109.793 0.310
202102 0.117 110.968 0.136
202105 0.301 113.576 0.343
202108 -0.256 115.421 -0.287
202111 0.021 117.269 0.023
202202 -0.253 119.703 -0.274
202205 0.192 123.323 0.201
202208 -0.664 124.958 -0.688
202211 0.171 125.607 0.176
202302 0.004 126.928 0.004
202305 0.376 128.314 0.379
202308 -0.668 129.538 -0.667
202311 0.117 129.548 0.117
202402 -0.407 129.419 -0.407

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AngioDynamics  (NAS:ANGO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AngioDynamics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics (AngioDynamics) Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. It generates maximum revenue from Endovascular Therapies. Geographically, the company derives a majority of its revenue from the United States.
Executives
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421